检测慢性便秘（CC）患者血清中5-羟色胺（5-HT）、生长抑素（SS）的表达水平及其影响因素。

收集自2016年10月至2017年2月于青岛市市立医院干部保健科就诊符合慢性便秘诊断标准的患者48例，其中男性31例，女性17例，平均年龄（70.0±12.7）岁，对照组为37例无便秘患者，男性24例，女性13例，平均年龄（64.4±9.0）岁。采用酶联免疫吸附实验法测定入组患者血清中5-HT、SS的表达水平；正态分布的计量资料采用（±s）表示，两组间比较采用t检验进行统计学分析。

慢性便秘患者血清中5-HT的含量为（23.30±6.57）pg/mL明显低于无便秘者（29.61±9.49）pg/mL，两者差异有统计学意义（t=-3.624，P=0.001）；而慢性便秘患者血清中SS的含量为（20.82±5.96）pg/mL明显高于对照组（16.92±6.47）pg/mL，差异有统计学意义（t=2.886，P=0.005）；不同年龄（t=-0.762，P=0.450），不同性别（t=-0.907，P=0.369），不同伴随症状如腹痛（t=0.894，P=0.376）、腹胀（t=-0.711，P=0.480）、排便费力（t=-1.534，P=0.132）、排便不尽感（t=1.339，P=0.187）的慢性便秘患者血清中5-HT的表达差异均无统计学意义（P>0.05）；不同年龄（t=-0.694，P=0.491），不同性别（t=-0.028，P=0.977），有无临床伴随症状如腹痛（t=-0.095，P=0.925）、腹胀（t=0.546，P=0.587）、排便费力（t=-1.391，P=0.171）、排便不尽感（t=0.110，P=0.913）的慢性便秘患者血清中SS的表达差异均无统计学意义（P>0.05）。

5-HT、SS在慢性便秘患者血清中的表达有其特点，年龄、性别及有无临床伴随症状对便秘患者血清中5-HT、SS的表达无明显影响。

To investigate the expression level of 5-hydroxytryptamine (5-HT) or somatostatin (SS) in serum of patients with chronic constipation and its influencing factors.

Patients were enrolled from October 2016 to February 2017 in Department of Healthcare, Qingdao Municipal Hospital, including patients with chronic constipation 48 cases, 31 male patients and 17 female patients, mean age was (70.0±12.7) years old; And total number of 37 patients without constipation as a control group, including male patients 24 cases and female patients 13 cases, average age was (64.4±9.0) years old. Enzyme -linked immunosorbent assay was used to determine the content of 5-HT and SS in the serum of the patients. The measurement data with normal distribution was presented as ±s, and the comparison between groups were analyzed using the t test.

The expression level of 5-HT in serum of patients with chronic constipation (23.30±6.57) pg/ml was significantly lower than that of control group (29.61±9.49) pg/mL, the difference was statistically significant (t=-3.624, P=0.001); the expression level of SS in serum of patients with chronic constipation (20.82±5.96) pg/mL was significantly higher than the control group (16.92±6.47) pg/mL, the difference was statistically significant (t=2.886, P=0.005); The expression level of 5-HT in serum of patients with chronic constipation of different ages (t=-0.762, P=0.450), different gender (t=-0.907, P=0.369), and different clinical symptoms as abdominal pain (t=0.894, P=0.376) 、abdominal distention (t=-0.711, P=0.480)、defecation effort (t=-1.534, P=0.132) 、defecation incompletion (t=1.339, P=0.187) was no significant difference (P>0.05). And the expression level of SS in serum of patients with chronic constipation of different ages (t=-0.694, P=0.491), different gender (t=-0.028, P=0.977), and different clinical symptoms as abdominal pain (t=-0.095, P=0.925) 、abdominal distention (t=0.546, P=0.587)、defecation effort (t=-1.391, P=0.171) 、defecation incompletion (t=0.110, P=0.913) was no significant difference (P>0.05).

The expression level of 5-HT and SS in serum of the patients with chronic constipation have some characteristics. Gender or age and clinical symptoms are no significant influence with the expression level of 5-HT and SS in the serum of the patients with constipation.